Marks BD - Search Results

1

Highly miniaturized formats for in vitro drug metabolism assays using vivid fluorescent substrates and recombinant human cytochrome P450 enzymes.

Trubetskoy OV, Gibson JR, Marks BD. Trubetskoy OV, et al. Among authors: marks bd. J Biomol Screen. 2005 Feb;10(1):56-66. doi: 10.1177/1087057104269731. J Biomol Screen. 2005. PMID: 15695344

2

A substrate-independent TR-FRET histone deacetylase inhibitor assay.

Marks BD, Fakhoury SA, Frazee WJ, Eliason HC, Riddle SM. Marks BD, et al. J Biomol Screen. 2011 Dec;16(10):1247-53. doi: 10.1177/1087057111422102. Epub 2011 Sep 21. J Biomol Screen. 2011. PMID: 21940713

3

Development and applications of a broad-coverage, TR-FRET-based kinase binding assay platform.

Lebakken CS, Riddle SM, Singh U, Frazee WJ, Eliason HC, Gao Y, Reichling LJ, Marks BD, Vogel KW. Lebakken CS, et al. Among authors: marks bd. J Biomol Screen. 2009 Sep;14(8):924-35. doi: 10.1177/1087057109339207. Epub 2009 Jun 29. J Biomol Screen. 2009. PMID: 19564447

4

Multiparameter analysis of a screen for progesterone receptor ligands: comparing fluorescence lifetime and fluorescence polarization measurements.

Marks BD, Qadir N, Eliason HC, Shekhani MS, Doering K, Vogel KW. Marks BD, et al. Assay Drug Dev Technol. 2005 Dec;3(6):613-22. doi: 10.1089/adt.2005.3.613. Assay Drug Dev Technol. 2005. PMID: 16438657

5

High-throughput screening assays for the assessment of CYP2C9*1, CYP2C9*2, and CYP2C9*3 metabolism using fluorogenic Vivid substrates.

Marks BD, Thompson DV, Goossens TA, Trubetskoy OV. Marks BD, et al. J Biomol Screen. 2004 Aug;9(5):439-49. doi: 10.1177/1087057104263440. J Biomol Screen. 2004. PMID: 15296644

6

High-throughput screening assays for CYP2B6 metabolism and inhibition using fluorogenic vivid substrates.

Marks BD, Goossens TA, Braun HA, Ozers MS, Smith RW, Lebakken C, Trubetskoy OV. Marks BD, et al. AAPS PharmSci. 2003;5(2):E18. doi: 10.1208/ps050218. AAPS PharmSci. 2003. PMID: 12866948 Free PMC article.

7

A high throughput screening assay to screen for CYP2E1 metabolism and inhibition using a fluorogenic vivid p450 substrate.

Marks BD, Smith RW, Braun HA, Goossens TA, Christenson M, Ozers MS, Lebakken CS, Trubetskoy OV. Marks BD, et al. Assay Drug Dev Technol. 2002 Nov;1(1 Pt 1):73-81. doi: 10.1089/154065802761001329. Assay Drug Dev Technol. 2002. PMID: 15090158

8

A simultaneous assessment of CYP3A4 metabolism and induction in the DPX-2 cell line.

Trubetskoy O, Marks B, Zielinski T, Yueh MF, Raucy J. Trubetskoy O, et al. AAPS J. 2005 Mar 4;7(1):E6-13. doi: 10.1208/aapsj070102. AAPS J. 2005. PMID: 16146350 Free PMC article.

9

Development of a coactivator displacement assay for the orphan receptor estrogen-related receptor-gamma using time-resolved fluorescence resonance energy transfer.

Gowda K, Marks BD, Zielinski TK, Ozers MS. Gowda K, et al. Among authors: marks bd. Anal Biochem. 2006 Oct 1;357(1):105-15. doi: 10.1016/j.ab.2006.06.029. Epub 2006 Jul 10. Anal Biochem. 2006. PMID: 16889744

10

The androgen receptor T877A mutant recruits LXXLL and FXXLF peptides differently than wild-type androgen receptor in a time-resolved fluorescence resonance energy transfer assay.

Ozers MS, Marks BD, Gowda K, Kupcho KR, Ervin KM, De Rosier T, Qadir N, Eliason HC, Riddle SM, Shekhani MS. Ozers MS, et al. Among authors: marks bd. Biochemistry. 2007 Jan 23;46(3):683-95. doi: 10.1021/bi061321b. Biochemistry. 2007. PMID: 17223690

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results